Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Propiedadiniciados 25.37% · instituciones 2.69%
En EUR · a Oct 19, 2026
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de OSE IMMUNOTHERAPEUTICS. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; ABBV-230, an agonist antibody against ChemR23 to resolve chronic inflammation; and CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a new technology of bispecific checkpoint inhibitors targeting the PD1 receptor and other innovative targets. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Fuente de información de mercado · Oct 19, 2026
Cronología en el mercado · historial completo
1 compra4 ventas— precio de cierrebarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Señales | Detalle |
|---|---|---|---|---|
| Alexis Peyroles | Otro | n/d (Operación sin contrapartida en efectivo: la notificación indica precio cero (concesión, donación, ejercicio)) | AMF |
| Didier Hoch | Ejercicio | $41.9K | AMF |
| Eric Leire | Ejercicio | $419.3K | AMF |
| MARYONNE HIANCE | Venta | $321.9K | AMF |
| ANNE-LAURE AUTRET-CORNET | Venta | $107.1K | AMF |
| MARYONNE HIANCE | Ejercicio | $38.4K | AMF |
| DOMINIQUE COSTANTINI | Ejercicio | $38.3K | AMF |
| Didier Hoch | OtroD (derivado) | $38.4K | AMF |
| Didier Hoch | Venta | $49.3K | AMF |
| MARYONNE HIANCE | Venta | $343K | AMF |
| DOMINIQUE COSTANTINI | Compra | $246.8K | conv 59Primera en 12 meses | AMF |